On April 21, 2020 Blue Earth Diagnostics Ltd, a Bracco company focused on molecular imaging diagnostics, reported expanded access to Axumin (fluciclovine (18F)) in Europe (Press release, Blue Earth Diagnostics, APR 21, 2020, View Source [SID1234556470]). The first commercial delivery of Axumin was made in Slovakia in April 2020. This was possible through the Blue Earth Diagnostics’ distribution partner in Slovakia, MGP, spol. s r. o. Axumin is a PET imaging agent approved in the European Union for use in men with suspected recurrence of prostate cancer. Axumin is commercially available in Belgium, Luxembourg, Italy, France, Norway, the Czech Republic, The Netherlands, Austria and, now, Slovakia, with further European countries set to follow soon.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Prostate cancer is a leading cause of cancer death in men. While most primary prostate cancer can be successfully treated, recurrence occurs in up to one-third of patients. Recurrent disease is typically detected by a rise in PSA levels but often the location and extent of the disease cannot be detected by conventional imaging. Of those who suffer biochemical recurrence, approximately one-third develop metastatic prostate cancer. Axumin was developed to target the increased amino acid transport that occurs in many cancers, including prostate cancer. It is labelled with the radioisotope (18F), enabling it to be visualized in the body with PET imaging.
Dr. Jonathan Allis, Chief Executive Officer of Blue Earth Diagnostics said, "We are very pleased that Axumin is now available in Slovakia. Expansion of supply into this new European country demonstrates the productive relationships that we have with our manufacturing and distribution partners, and supports our mission to make Axumin commercially available to clinicians and their patients across Europe."
Karel Zeleny, Chief Executive Officer of MGP commented, "We are proud of our continuing partnership with Blue Earth Diagnostics, and are happy to be able to distribute Axumin to another new market, contributing to the management of patients with prostate cancer recurrence."